PRIMARY OBJECTIVES:~I. To evaluate the feasibility of the ePRO platform by describing the proportion of participants who engage with the ePRO tool via virtual care chat at least once after enrollment.~II. To investigate the potential differences in health-related quality of life (HRQoL) by comparing the change in overall score of EuroQol five-dimensional Questionnaire (EQ-5D) index.~SECONDARY OBJECTIVES:~I. To evaluate the degree of engagement with virtual care chat as defined by the proportion of chat modules completed.~II. To measure the potential differences in health-related quality of life (HRQoL).~III. To describe the symptom experience of participants in the intervention arm.~IV. To evaluate the performance of clinical escalation rules and impact on clinic workflow and efficiency.~V. To prospectively validate a risk model predicting emergency department (ED) visits and admissions due to cancer treatment side effects.~EXPLORATORY OBJECTIVES:~I. To compare unplanned ED visits and hospitalizations between intervention arm and control arm.~II. To compare referral patterns to Symptom Management Clinic. III. To compare concordance between participant self-reported and provider assigned Eastern Cooperative Oncology Group (ECOG) Performance Status.
This is a randomized trial of patients with gastrointestinal (GI) cancers treated at University of California, San Francisco (UCSF) who are starting a new line of systemic therapy to evaluate the feasibility of electronic patient reported outcome (ePRO) platform.